SEARCH

SEARCH BY CITATION

References

  • 1
    Avery RL, Roberts D. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia. L1210. Eur J Cancer 1974; 10: 425429.
  • 2
    Bertino JR, Mosher MB, DeConti RC. Chemotherapy of cancer of the head and neck. Cancer 1973; 31: 11411149.
  • 3
    Capizzi RL, DeConti RC, Marsh JC, Bertino JR. Methotrexate therapy of head and neck cancer: Improvement in therapeutic index by the use of leucovorin “rescue.” Cancer Res 1970; 30: 17821788.
  • 4
    Chu MY, Fischer GA. Effects of cytosine arabinoside on the cell viability and uptake of deoxypyrimidine nucleosides in L5178Y cells. Biochem Pharmacol 1968; 17: 741751.
  • 5
    Clinical staging system for carcinoma of the oral cavity. Chicago: American Joint Committee for Cancer Staging and End Results Reporting, 1967; 112.
  • 6
    Clinical staging system for carcinoma of the pharynx (nasopharynx, oropharynx, hypopharynx). Chicago: American Joint Committee for Cancer Staging and End Results Reporting, 1965; 9.
  • 7
    Cox DR. Analysis of binary data. London: Methuen & Co. Ltd, 1970, 8791.
  • 8
    Cox DR. Regression models of life tables. J Royal Stat Soc Series B. 1972; 34: 187.
  • 9
    DeConti RC. Phase III Comparison of methotrexate with leucovorin vs methotrexate alone vs. a combination of methotrexate plus leucovorin, cyclophosphamide and cytosine arabinoside in head and neck cancer. Proc Am Soc Clin Oncol 1976; 17: 248.
  • 10
    Djerassi I, Royer G, Treat C, et al. Management of childhood lymphosarcoma and RCS with high dose intermittent methotrexate and citrovorum factor. Proc Am Assoc Cancer Res 1968; 9: 18.
  • 11
    Djerassi I, Rominger CJ, Kim JS, Turchi J, Suvansri U, Hughes D. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer. Cancer 1972; 30: 2230.
  • 12
    Gibbons JD. Nonparametric statistical inference. New York: McGraw-Hill, 1971: 146.
  • 13
    Goldin A, Mantel M, Greenhouse SW, Venditti JM, Humphreys SR. Effect of delayed administration of citrovorum factor on the antileukemic effectiveness of aminopterin in mice. Cancer Res 1954; 14: 4348.
  • 14
    Goldin A, Venditti JM, Kline I, Mantel N. Erradication of leukemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 1966; 212: 15481550.
  • 15
    Hong WK, Shapshay SM, Bhutani R, et al. Induction chemotherapy in advanced squamous head and neck carcinoma with high dose cis-platinum and bleomycin infusion. Cancer 1979; 44: 1925.
  • 16
    Hryniuk W, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical biochemical correlates. J Clin Invest 1969; 48: 21402155.
  • 17
    Huffman DH, Wan SH, Azarnoff DL, Hoogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1973; 14: 572579.
  • 18
    Jaffe N, Frei E III, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum factor treatment of osteogenic sarcoma. N Engl J Med 1974; 291: 994997.
  • 19
    Jaffe M, Frei E III, Watts H, and Traggis D. High dose methotrexate in osteogenic sarcoma: A 5-year experience. Cancer Treat Rep 1978; 62: 259264.
  • 20
    James AG. Cancer prognosis manual. New York: American Cancer Society.
  • 21
    Lefkowitz E, Papac RJ, Bertino JR. Head and neck cancer III. Toxicity of 24-hour infusions of methotrexate (NSC-740) and protection by leucovorin (NSC-3590) in patients with epidermoid carcinomas. Cancer Chemother Rep 1967; 51: 305311.
  • 22
    Levitt M, Mosher MB, DeConti RC, et al. Improved therapeutic index of methotrexate with “leucovorin rescue.” Cancer Res 1973; 33: 17291734.
  • 23
    Livingston RC, Carter SK. Single agents in cancer chemotherapy. New York: IFI/Plenum, 1970.
  • 24
    Mills EED. Intermittent intravenous methotrexate in the treatment of advanced epidermoid carcinoma. S. African Med J 1972; 46: 398401.
  • 25
    Mitchell MS, Wawro NW, DeConti RC, Kaplan SR, Papac RJ, Bertino JR. Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinomas of the head and neck. Cancer Res 1968; 28: 10881094.
  • 26
    Papac RJ, Fischer JJ. Cytosine arabinoside (NSC-63878) in the treatment of epidermoid carcinomas of the head and neck. Cancer Chemother Rep 1971; 55: 193197.
  • 27
    Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J Royal Stat Soc Series A. 1972; 135: 183198.
  • 28
    Pitman S, Frei E. Weekly methotrexate citrovorum (MTX-CF) with alkalinization: Tumor response in a phase II study. Proc Am Assoc Cancer Res 1977; 18: 494.
  • 29
    Sandberg JS, Goldin A. The use of leucovorin orally in normal and leukemic L1210 mice to prevent the toxicity and gastrointestinal lesions caused by high doses of methotrexate. Cancer Res 1970; 30: 12761280.
  • 30
    Sealy R, Helman P. Treatment of head and neck cancer with intra-arterial cytotoxic drugs and radiotherapy. Cancer 1972; 30: 187189.
  • 31
    Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297: 630634.
  • 32
    Vogl SE, Kaplan BH. Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II in an effective out-patient schedule. Cancer 1979; 44: 2631.
  • 33
    Wittes RE, Brescia R, Young CW, Golbey BB, Krakoff RH. Combination chemotherapy with cis-platinum and bleomycin in tumors of the head and neck. Oncology 1975; 32: 202207.
  • 34
    Wittes RE, Cvitkovic E, Shah J, Gerold FP, Strong GW. Cis-dichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 1977; 61: 359366.